Angiotech BioMaterials Corp.
Division of Angiotech Pharmaceuticals Inc.
Latest From Angiotech BioMaterials Corp.
Recent 510(k) clearances include Andrew Technologies’ HydraSolve lipoplasty system for fat reduction; Insulet’s next-generation, tubeless OmniPod insulin pump; and PhysioSonics’ Presto 1000 cerebral blood flow monitor.
Ever since drug-eluting stents became such an overwhelming success, the health care products industry has been trying to wrap its arms around convergence opportunities, in which the combination of drugs and devices is worth more than the sum of the parts and pieces. The ongoing debate has been: which part of combination products is it better to own--the drug or the device? According to one company that would probably define itself as the only "pure play" in convergence, Angiotech Pharmaceuticals Inc., the answer is: both. Angiotech just acquired diversified device manufacturer AMI Holdings.
Angiotech positions itself as the first specialty pharmaceutical company dedicated to the drug/device interface. Best known as Boston-Scientific's pharmaceutical partner on the Taxus drug-eluting stent, Angiotech has created a large body of intellectual property around drug-device combinations. Focusing on the essential biological mechanisms involved in device failures, the company develops existing drugs for new applications in combination products for surgical markets, and it also owns a broad-based portfolio of drug eluting biomaterials. Now, as it looks to life after drug-eluting stents, Angiotech has plans to offer drug plus device combinations in peripheral vascular disease, orthopedics, ob/gyn surgery, and anti-infective coatings. It will thus face the challenge of managing, as a small to mid-sized company, a great variety of projects with limited resources. To lessen reliance on partners, going forward, it aims to capture an increasing proportion of revenues from product sales, taking some products from preclinical stage to market itself. But as a mid-sized company, it might have to choose between sacrificing a percentage of product sales to partners that provide development or distribution expertise that it doesn't have, or narrowly focusing on markets that it can address itself, but limiting its opportunities in a niche specialty.
Obtaining proof-of-concept data is often the key inflection point in the life cycle of a compound. How well a biotech anticipates and plans for the transition from one stage of business to the next may similarly be a critical factor in the company's overall success, according to survey of biotech management practices by Mardis, Aibel & Associates.
- Surgical Equipment & Devices
- Therapeutic Areas
- Wound Healing & Tissue Repair
- Cohesion Technologies Inc.
- North America
- Parent & Subsidiaries
- Angiotech Pharmaceuticals Inc.
- Senior Management
William Mavity, Pres. & CEO
George Y Daniloff, MD, PhD, VP, R&D
David Smith, VP, Mktg. & Bus. Dev.
Sharon S Kokubun, VP, Fin.
- Contact Info
Angiotech BioMaterials Corp.
Phone: (650) 320-5500
2500 Faber Pl.
Palo Alto, CA 94303